IS
Undisclosed pharmaceutical company (InnoCentive 'Seeker')

Alternative, Scalable Synthetic Routes for Phase II-ready Small Molecule

Pays $50,000 for a scalable, low-cost synthesis route for a Phase II drug candidate.

Alternative, Scalable Synthetic Routes for Phase II-ready Small Molecule is a challenge from an undisclosed pharmaceutical company, posted as an InnoCentive 'Seeker,' paying $50,000 to chemists, process-chemistry experts, start-ups, academic groups and organisations who can propose an alternative synthetic route to manufacture a specific clinical-candidate small molecule — a delta opioid receptor

Looking for chemists, process-chemistry experts, start-ups, academic groups and organisations proposing an alternative synthetic route to manufacture a specific clinical-candidate small molecule (a delta opioid receptor agonist for neuropathic pain) at multi-tonne, GMP-ready scale. Solutions should sit at Technology Readiness Level 4-6 and keep cost of goods below 3,000 EUR/kg API, ideally under 1,000 EUR/kg.

CycleiHow often this grant runs - e.g. annually, on a rolling basis, or a one-off call.No fixed schedule
Next deadlineiThe next date applications are due. Rolling means you can apply any time.-
Decision timeiTypical time from the deadline to the funder's decision.-
Project durationiHow long the funded work is expected to run.-
Award typeiThe form of funding - grant, equity, loan, tax credit, etc.Prize
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.-
Funding pooliThe total budget available across all awards in this round.-

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see the timeline

Sign up free to see where teams trip up

Guides for this application

All guides →